Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NewQuest Capital Partners is a leading Asia-Pacific-focused secondary private equity platform, specializing in acquiring existing private equity positions and providing liquidity solutions to asset owners and limited partners. It was established in 2011 as a spin-out from Bank of America Merrill Lynch’s Asian Private Equity team and was acquired by TPG in January 2022, now operating as TPG NewQuest. The firm manages approximately $2.6 billion in assets and has completed secondary transactions in over 80 companies across various sectors, including healthcare where it has made select investments (e.g., Cloudnine hospitals in India). NewQuest is not a biotech or pharma company and does not develop drugs, but invests in companies across business services, consumer, financial services, healthcare, and TMT (technology, media, telecom).
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NewQuest Capital Partners.